Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitors

This page shows the latest JAK inhibitors news and features for those working in and with pharma, biotech and healthcare.

'Therapeutic overcrowding' could hit big pharma returns

'Therapeutic overcrowding' could hit big pharma returns

Another problem is that with checkpoint inhibitors being tested in just about every type of cancer, there is a potential shortfall of patients required for clinical trials. ... novel drugs” such as IL-23 inhibitors and JAK inhibitors.

Latest news

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Pharma deals during December 2012 Pharma deals during December 2012

    company with an annual cash burn of $30m developing orally active JAK 1 / JAK 2 kinase inhibitors and with a lead product, CYT387, in clinical development and complementary to Gilead's ... YM Bioscience / Gilead. Company acquisition. JAK kinase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics